Last reviewed 2026-05-22 · How we verify

triamcinolone XRG5029

Sanofi · Phase 3 active Small molecule Under review Quality 0/100

triamcinolone XRG5029 is a Corticosteroid Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Inflammatory and autoimmune conditions (specific Phase 3 indication unknown). Also known as: Nasacort®.

Triamcinolone is a synthetic corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

Triamcinolone XRG5029 is a small molecule glucocorticoid receptor agonist, classified as an agonist. It is being studied for the treatment of perennial allergic rhinitis, specifically in comparison to fluticasone in a clinical trial.

Likelihood of approval

62.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
Big-pharma sponsor +3.0pp
Sanofi is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	triamcinolone XRG5029
Also known as	Nasacort®
Sponsor	Sanofi
Drug class	Corticosteroid
Target	Glucocorticoid receptor
Modality	Small molecule
Therapeutic area	Immunology / Inflammation
Phase	Phase 3

Mechanism of action

Triamcinolone exerts its anti-inflammatory effects through glucocorticoid receptor activation, which leads to decreased production of inflammatory mediators and reduced immune cell activation. The XRG5029 designation suggests this may be a modified or extended-release formulation of triamcinolone designed to optimize pharmacokinetics or reduce dosing frequency. As a corticosteroid, it broadly suppresses both innate and adaptive immune responses.

Approved indications

Inflammatory and autoimmune conditions (specific Phase 3 indication unknown)

Common side effects

Immunosuppression / increased infection risk
Hyperglycemia
Hypertension
Osteoporosis (with chronic use)
Adrenal suppression

Key clinical trials

A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

triamcinolone XRG5029 CI brief — competitive landscape report
triamcinolone XRG5029 updates RSS · CI watch RSS
Sanofi portfolio CI

Frequently asked questions about triamcinolone XRG5029

What is triamcinolone XRG5029?

triamcinolone XRG5029 is a Corticosteroid drug developed by Sanofi, indicated for Inflammatory and autoimmune conditions (specific Phase 3 indication unknown).

How does triamcinolone XRG5029 work?

Triamcinolone is a synthetic corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

What is triamcinolone XRG5029 used for?

triamcinolone XRG5029 is indicated for Inflammatory and autoimmune conditions (specific Phase 3 indication unknown).

Who makes triamcinolone XRG5029?

triamcinolone XRG5029 is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

Is triamcinolone XRG5029 also known as anything else?

triamcinolone XRG5029 is also known as Nasacort®.

What drug class is triamcinolone XRG5029 in?

triamcinolone XRG5029 belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

What development phase is triamcinolone XRG5029 in?

triamcinolone XRG5029 is in Phase 3.

What are the side effects of triamcinolone XRG5029?

Common side effects of triamcinolone XRG5029 include Immunosuppression / increased infection risk, Hyperglycemia, Hypertension, Osteoporosis (with chronic use), Adrenal suppression.

What does triamcinolone XRG5029 target?

triamcinolone XRG5029 targets Glucocorticoid receptor and is a Corticosteroid.

Drug class: All Corticosteroid drugs
Target: All drugs targeting Glucocorticoid receptor
Manufacturer: Sanofi — full pipeline
Therapeutic area: All drugs in Immunology / Inflammation
Indication: Drugs for Inflammatory and autoimmune conditions (specific Phase 3 indication unknown)
Also known as: Nasacort®

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing